AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33101409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SHBG levels
Number of subjects: 0
Study 33101409 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG as a predictor
Number of subjects: 0
Study 33101409 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG <26.75 mmol/L
Number of subjects: 0
Study 33101409 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG levels
Number of subjects: 0
Study 33101530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical activity during first-person virtual reality simulation of bicycle riding
Number of subjects: 0
Study 33101530 — intervention group
Group type: COMPARATOR
Intervention: Cortical activity at rest
Number of subjects: 0
Study 33101775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 0
Study 33101775 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 33102224 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and systemic therapy, specific details not available.
Number of subjects: 0
Study 33102224 — intervention group
Group type: COMPARATOR
Intervention: Control group details not available.
Number of subjects: 0
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418
Study 33102391 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418
Study 33102398 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with mFOLFIRINOX (10 cycles)
Number of subjects: 1
Study 33102398 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenocephalopancreasectomy after chemotherapy
Number of subjects: 1
Study 33102398 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy after 8 months from surgery due to liver and lung metastases
Number of subjects: 1
Study 33102510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented whey concentrate (FWC) drink rich in L-(+)-Lactic acid, consumed daily
Number of subjects: 18
Study 33102611 — intervention group
Group type: EXPERIMENTAL
Intervention: Democritus Digital Acuity Reading Test (DDART)
Number of subjects: 100
Study 33102611 — intervention group
Group type: COMPARATOR
Intervention: MNREAD-GR
Number of subjects: 100
Study 33103032 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-mg once-monthly risedronate
Number of subjects: 24
Study 33103032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33103200 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 84672
Study 33103200 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (Control)
Number of subjects: 84672
Study 33103200 — intervention group
Group type: COMPARATOR
Intervention: Zanamivir (Control)
Number of subjects: 84672
Study 33103200 — intervention group
Group type: COMPARATOR
Intervention: Laninamivir (Control)
Number of subjects: 84672
Study 33103545 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlide
Number of subjects: 2583
Study 33103545 — intervention group
Group type: COMPARATOR
Intervention: Prostar XL
Number of subjects: 2583
Study 33103591 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-COPD overlap (ACO) patients
Number of subjects: 2003
Study 33103591 — intervention group
Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 2003
Study 33103591 — intervention group
Group type: COMPARATOR
Intervention: Asthma patients
Number of subjects: 2003
Study 33103591 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO patients
Number of subjects: 2003
Study 33103591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of ACO
Number of subjects: 2003
Study 33104001 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological age model
Number of subjects: 100
Study 33104001 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 100
Study 33104014 — intervention group
Group type: EXPERIMENTAL
Intervention: LiverMultiScan (mpMRI) as a standardized diagnostic test for liver disease
Number of subjects: 1072
Study 33104014 — intervention group
Group type: COMPARATOR
Intervention: Standard care for NAFLD
Number of subjects: 1072
Study 33104014 — intervention group
Group type: EXPERIMENTAL
Intervention: LiverMultiScan (mpMRI)
Number of subjects: 1072
Study 33104056 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of hs-CRP
Number of subjects: 237
Study 33104056 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of VAT
Number of subjects: 237
Study 33104056 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening hs-CRP
Number of subjects: 237
Study 33104056 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved hs-CRP
Number of subjects: 237
Study 33104056 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased VAT
Number of subjects: 237
Study 33104201 — intervention group
Group type: EXPERIMENTAL
Intervention: Active S. stercoralis infection
Number of subjects: 668
Study 33104796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg twice daily for induction, followed by 10 mg twice daily for subsequent cycles, combined with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle.
Number of subjects: 25
Study 33104796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib and decitabine combination treatment.
Number of subjects: 25
Study 33104838 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 46
Study 33104865 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoids (ECs), N-acylethanolamines (NAEs), and N-acylphosphatidylethanolamines (NAPEs) concentrations in ileal fluids and plasma
Number of subjects: 35
Study 33104944 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental locus of control for injury prevention (measured by four items adapted from the Parental Health Beliefs Scales)
Number of subjects: 452
Study 33104944 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental locus of control for injury prevention over time (measured at 2, 6, 9, 12, and 24 months)
Number of subjects: 452
Study 33104944 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury-related LOC items
Number of subjects: 452
Study 33104972 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium-89 conjugated Pembrolizumab
Number of subjects: 0
Study 33105036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 39
Study 33105036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 39
Study 33105036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 39
Study 33105234 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based telemedicine
Number of subjects: 0
Study 33105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence interventions
Number of subjects: 0
Study 33105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic adherence sensors
Number of subjects: 0
Study 33105385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment for 4 weeks
Number of subjects: 15
Study 33105385 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (9% coverage)
Number of subjects: 0
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (83% coverage)
Number of subjects: 0
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (47% coverage)
Number of subjects: 0
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (88% coverage)
Number of subjects: 0
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: TasP
Number of subjects: 0
Study 33105397 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP and TasP combined scale-up
Number of subjects: 0
Study 33105397 — intervention group
Group type: COMPARATOR
Intervention: TasP scale-up alone
Number of subjects: 0
Study 33105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management of SSIs
Number of subjects: 325
Study 33105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management of SSIs
Number of subjects: 325
Study 33105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial SSIs
Number of subjects: 325
Study 33105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep or organ/space SSIs
Number of subjects: 325
Study 33105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SSI resolution
Number of subjects: 325
Study 33106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision medicine treatment based on prospective genomic profiling
Number of subjects: 0
Study 33107003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach program with customized electronic health record tools and clinical staff training.
Number of subjects: 8
Study 33107003 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized implementation team and advance mailing of introduction letter.
Number of subjects: 8
Study 33107145 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-circulating miRNA prognostic model (miR21, miR130b, miR155, miR28)
Number of subjects: 504
Study 33107145 — intervention group
Group type: COMPARATOR
Intervention: High-risk group based on 4-circulating miRNA model
Number of subjects: 504
Study 33107191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimension 3 scores in early AKI
Number of subjects: 0
Study 33107191 — intervention group
Group type: COMPARATOR
Intervention: Dimension 3 scores in TCMR
Number of subjects: 0
Study 33107191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimension 3 scores in kidneys from older donors
Number of subjects: 0
Study 33107189 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS platforms
Number of subjects: 72
Study 33107189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity PCR-based methodologies
Number of subjects: 72
Study 33107189 — intervention group
Group type: EXPERIMENTAL
Intervention: Different quantitative methods
Number of subjects: 72
Study 33107189 — intervention group
Group type: COMPARATOR
Intervention: Samples with MAF ≤ 0.5%
Number of subjects: 72
Study 33107189 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with brain metastases
Number of subjects: 72
Study 33107237 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1453
Study 33107237 — intervention group
Group type: COMPARATOR
Intervention: Non-monetary incentive for referral
Number of subjects: 1453
Study 33107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma with electromagnetic stimulation
Number of subjects: 0
Study 33107430 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 33107561 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartmate 3 (HM3)
Number of subjects: 540
Study 33107592 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone antagonists (selective (eplerenone), non-selective (spironolactone or canrenone), or non-steroidal mineralocorticoid antagonists (finerenone)) in combination with ACEi or ARB
Number of subjects: 5745
Study 33107798 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-resolution US
Number of subjects: 62
Study 33107798 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced US
Number of subjects: 62
Study 33107835 — intervention group
Group type: COMPARATOR
Intervention: rTMS sessions alone
Number of subjects: 100
Study 33107835 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS sessions plus iCBT
Number of subjects: 100
Study 33107983 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) at 50 mg, 75 mg, 100 mg, and 125 mg orally 3 times per week plus dexamethasone at 24 mg twice daily on days 1 to 5 every other week in a 28-day cycle.
Number of subjects: 36
Study 33107983 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat plus dexamethasone
Number of subjects: 36
Study 33108031 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) - Confirm Rx ICM implanted, programmed for VT ≥160 bpm for ≥8 intervals, AF ≥2 min, bradycardia ≤40 bpm or pause ≥3.0 s
Number of subjects: 30
Study 33108238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab alone (arm A)
Number of subjects: 83
Study 33108238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (arm B)
Number of subjects: 83
Study 33108243 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 57
Study 33108270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment with ≥6-hour use
Number of subjects: 45
Study 33108270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment with ≥4-hour use
Number of subjects: 45
Study 33108270 — intervention group
Group type: COMPARATOR
Intervention: IPF-OSA group
Number of subjects: 45
Study 33108270 — intervention group
Group type: COMPARATOR
Intervention: IPF group
Number of subjects: 45
Study 33108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 871
Study 33108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 871
Study 33108543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 33108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 871
Study 33109210 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCAm testing
Number of subjects: 341
Study 33109210 — intervention group
Group type: EXPERIMENTAL
Intervention: HRRm testing
Number of subjects: 341
Study 33109504 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly processed foods
Number of subjects: 46
Study 33109504 — intervention group
Group type: COMPARATOR
Intervention: Minimally processed foods
Number of subjects: 46
Study 33109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice intake (8 oz daily)
Number of subjects: 318
Study 33109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Water/Sugar-Free Beverage (SFB) intake (8 oz daily)
Number of subjects: 318
Study 33109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverages (SSB) intake (8 oz daily)
Number of subjects: 318
Study 33109505 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing (additional daily event)
Number of subjects: 318
Study 33109627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib and letrozole (400 mg of ribociclib and 2.5 mg of letrozole daily)
Number of subjects: 40
Study 33109637 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health campaigns (CHCs)
Number of subjects: 3299
Study 33109637 — intervention group
Group type: COMPARATOR
Intervention: Home-based testing
Number of subjects: 3299
Study 33109646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cog-Awareness ADL Scale
Number of subjects: 0
Study 33109646 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness ADL-task: Basic and Instrumental ADL performance-based test
Number of subjects: 0
Study 33109646 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic tests on anosognosia and cognitive functions
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL at diagnosis measured with the EORTC QLQ-C30
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage and tumour size at diagnosis
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years
Number of subjects: 0
Study 33109665 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 0
Study 33109667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and imaging biomarkers
Number of subjects: 164
Study 33109667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples taken on days 1-3 for brain-focused biomarkers
Number of subjects: 164
Study 33109667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated and timed brain MRI and spectroscopy biomarkers
Number of subjects: 164
Study 33109675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) programme with a minimum implementation level of 70%
Number of subjects: 0
Study 33109675 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who fail to reach the 70% implementation level)
Number of subjects: 0
Study 33109737 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Number of subjects: 43
Study 33109741 — intervention group
Group type: EXPERIMENTAL
Intervention: 472-gene model
Number of subjects: 0
Study 33109741 — intervention group
Group type: EXPERIMENTAL
Intervention: 99 and 200 gene subsets
Number of subjects: 0
Study 33109741 — intervention group
Group type: EXPERIMENTAL
Intervention: FFPE-based classifier
Number of subjects: 0
Study 33109741 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS classification
Number of subjects: 0
Study 33110036 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic VMS
Number of subjects: 30
Study 33110439 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein concentrate with BC30 (MPCBC30)
Number of subjects: 30
Study 33110439 — intervention group
Group type: COMPARATOR
Intervention: Milk protein concentrate without BC30 (MPC)
Number of subjects: 30
Study 33110445 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high SDQ scores (≥ 14)
Number of subjects: 148
Study 33110445 — intervention group
Group type: COMPARATOR
Intervention: Children with low SDQ scores (< 14)
Number of subjects: 148
Study 33110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative testing based on symptoms or suspicious radiologic findings recommended in local guidelines
Number of subjects: 936
Study 33110590 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal testing for every surgical patient
Number of subjects: 936
Study 33110590 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital COVID-19 infection reporting
Number of subjects: 936
Study 33110623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense upper limb intervention
Number of subjects: 16
Study 33110622 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cholecalciferol (1600 IU/day for < 1 year, 2400 IU/day for > 1 year)
Number of subjects: 41
Study 33110622 — intervention group
Group type: COMPARATOR
Intervention: Usual care cholecalciferol (< 1 year = 400 IU/day, > 1 year = 600 IU/day)
Number of subjects: 41
Study 33110944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 33111240 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIM-ER intervention education components
Number of subjects: 197
Study 33111240 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIM-ER intervention
Number of subjects: 197
Study 33111240 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey assessing attitudes and knowledge on end-of-life care
Number of subjects: 197
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 1008
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1008
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 1008
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1008
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 1008
Study 33111650 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mental health and substance use symptoms
Number of subjects: 1008
Study 33112227 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire with BMI threshold of 27.5 kg/m² for Chinese and Indian patients
Number of subjects: 1205
Study 33112227 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire with BMI threshold of 35 kg/m² for Malay and Caucasian patients
Number of subjects: 1205
Study 33112227 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang threshold of 4 or greater
Number of subjects: 1205
Study 33112242 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO follow-up using a weekly questionnaire evaluating symptoms and an urgency algorithm for alerts.
Number of subjects: 37
Study 33112424 — intervention group
Group type: COMPARATOR
Intervention: Physical activity promotion, exercise training, and inspiratory muscle training
Number of subjects: 924
Study 33112968 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haploSCT) using KIR-ligand mismatched donor with reduced-intensity conditioning and post-transplantation cyclophosphamide (PTCY) for GVHD prophylaxis
Number of subjects: 12
Study 33112968 — intervention group
Group type: COMPARATOR
Intervention: Conventional allogeneic stem cell transplantation (alloSCT)
Number of subjects: 12
Study 33113214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CCNU/TMZ therapy
Number of subjects: 129
Study 33113214 — intervention group
Group type: EXPERIMENTAL
Intervention: qMSP ratio
Number of subjects: 129
Study 33113214 — intervention group
Group type: EXPERIMENTAL
Intervention: qMSP, PSQ, MGMT-STP27
Number of subjects: 129
Study 33114652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atu027 (0.235 mg/kg twice weekly) + Gemcitabine
Number of subjects: 23
Study 33114652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atu027 (0.235 mg/kg once weekly) + Gemcitabine
Number of subjects: 23